Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age

1992 ◽  
Vol 75 (4) ◽  
pp. 1125-1132 ◽  
Author(s):  
P. J. Coon
Keyword(s):  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Body Fat ◽  
Fat Distribution ◽  
Body Fat Distribution

Role of body fat distribution in the decline in insulin sensitivity and glucose tolerance with age.

1992 ◽  
Vol 75 (4) ◽  
pp. 1125-1132 ◽  
Author(s):  
P J Coon ◽  
E M Rogus ◽  
D Drinkwater ◽  
D C Muller ◽  
A P Goldberg
Keyword(s):  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Body Fat ◽  
Fat Distribution ◽  
Body Fat Distribution

Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients

Metabolism ◽  
2008 ◽  
Vol 57 (4) ◽  
pp. 479-487 ◽  
Author(s):  
You-Cheol Hwang ◽  
Eun Young Lee ◽  
Won Jae Lee ◽  
Bong Soo Cha ◽  
Kun-Ho Yoon ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Insulin Sensitivity ◽  
Body Fat ◽  
Fat Distribution ◽  
Body Fat Distribution ◽  
Korean Type

scholarly journals Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia

2009 ◽  
Vol 161 (6) ◽  
pp. 887-894 ◽  
Author(s):  
Jeanne Margot Kroese ◽  
Christiaan F Mooij ◽  
Marinette van der Graaf ◽  
Ad R M M Hermus ◽  
Cees J Tack
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Insulin Sensitivity ◽  
Body Fat ◽  
Matched Control ◽  
Fat Distribution ◽  
Body Fat Distribution ◽  
Adrenal Hyperplasia ◽  
Insulin Resistant ◽  
Steroid Profiles

ContextPatients with congenital adrenal hyperplasia (CAH) are chronically treated with supraphysiological doses of glucocorticoids, which are known to induce insulin resistance. Thiazolidinediones might reverse this effect and improve insulin sensitivity.ObjectivesTo assess insulin sensitivity in CAH patients and the effect of pioglitazone treatment on insulin sensitivity in CAH patients. Secondary objectives were the effects of treatment with pioglitazone on blood pressure, body fat distribution, lipid, and steroid profiles.DesignRandomized placebo controlled crossover trial.ParticipantsTwelve CAH patients and 12 body mass and age-matched control subjects.InterventionSixteen-week treatment with pioglitazone (45 mg/day) or placebo.Main outcome measureInsulin sensitivity measured by euglycemic clamp and oral glucose tolerance test. Further measures were 24-h blood pressure profiles, body fat distribution measured by magnetic resonance imaging, dual energy x-ray absorptiometry (DEXA) and bioimpedance procedures, liver fat by magnetic resonance spectroscopy, lipid, and steroid profiles.ResultsCAH patients were insulin resistant compared with healthy controls. Treatment with pioglitazone significantly improved insulin sensitivity in CAH patients (glucose infusion rate (GIR) from 28.5±11.6 to 38.9±11.0 μmol/kg per min, P=0.000, GIR in controls 46.2±23.4 μmol/kg per min, P<0.05 versus CAH). Treatment with pioglitazone decreased blood pressure (systolic: 124.0±13.6 vs 127.0±14.9 mmHg, P<0.001, diastolic: 72.8±11.5 vs 77.4±12.6 mmHg, P<0.001). No changes in body fat distribution, lipid, and steroid profiles were observed.ConclusionsCAH patients are insulin resistant compared with matched control subjects. Treatment with pioglitazone improves insulin sensitivity and decreases blood pressure in CAH patients.

Role of Genes in Obesity and Body Fat Distribution

JAMA ◽  
2015 ◽  
Vol 313 (13) ◽  
pp. 1305
Author(s):  
Tracy Hampton
Keyword(s):  
Body Fat ◽  
Fat Distribution ◽  
Body Fat Distribution
Sign in / Sign up

Export Citation Format

Share Document